Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
Standard
Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma. / Geidel, Glenn; Heidrich, Isabel; Kött, Julian; Schneider, Stefan W; Pantel, Klaus; Gebhardt, Christoffer.
in: NPJ PRECIS ONCOL, Jahrgang 6, Nr. 1, 17, 23.03.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma
AU - Geidel, Glenn
AU - Heidrich, Isabel
AU - Kött, Julian
AU - Schneider, Stefan W
AU - Pantel, Klaus
AU - Gebhardt, Christoffer
N1 - © 2022. The Author(s).
PY - 2022/3/23
Y1 - 2022/3/23
N2 - Advanced cutaneous squamous cell carcinoma (cSCC) encompasses unresectable and metastatic disease. Although immune checkpoint inhibition has been approved for this entity recently, a considerable proportion of cases is associated with significant morbidity and mortality. Clinical, histopathological, and radiological criteria are used for current diagnostics, classification, and therapeutic decision-making. The identification of complex molecular biomarkers to accurately stratify patients is a not yet accomplished requirement to further shift current diagnostics and care to a personalized precision medicine. This article highlights new insights into the mutational profile of cSCC, summarizes current diagnostic and therapeutic standards, and discusses emerging diagnostic approaches with emphasis on liquid biopsy and tumor tissue-based analyses.
AB - Advanced cutaneous squamous cell carcinoma (cSCC) encompasses unresectable and metastatic disease. Although immune checkpoint inhibition has been approved for this entity recently, a considerable proportion of cases is associated with significant morbidity and mortality. Clinical, histopathological, and radiological criteria are used for current diagnostics, classification, and therapeutic decision-making. The identification of complex molecular biomarkers to accurately stratify patients is a not yet accomplished requirement to further shift current diagnostics and care to a personalized precision medicine. This article highlights new insights into the mutational profile of cSCC, summarizes current diagnostic and therapeutic standards, and discusses emerging diagnostic approaches with emphasis on liquid biopsy and tumor tissue-based analyses.
U2 - 10.1038/s41698-022-00261-z
DO - 10.1038/s41698-022-00261-z
M3 - SCORING: Review article
C2 - 35322182
VL - 6
JO - NPJ PRECIS ONCOL
JF - NPJ PRECIS ONCOL
SN - 2397-768X
IS - 1
M1 - 17
ER -